[New perspectives in diagnostic. High-resolution optical coherence tomography for age-related macular degeneration].
BACKGROUND
Recent advances in optical coherence tomography (OCT) have made it possible to increase resolution and scan velocities so that even greater central areas of the retina can be scanned. The aim of this study is to describe the possibilities offered by this new technology for age-related macular degeneration.


METHODS
The study included 20 patients with confirmed active choroidal neovascularization (CNV) as well as pigment epithelial detachment (PED). Three-dimensional imaging was performed with a high-definition raster scanning OCT system (HD-OCT) with an axial resolution of 6 microm and a scan velocity of up to 20,000 A-scans/s. The scanned area measured 6 x 6 mm with a depth of 2 mm. Two-dimensional imaging was carried out with a StratusOCT (Carl Zeiss Meditec).


RESULTS
Comparison of the individual slices showed improved identification of intra- and subretinal structures with the HD-OCT. Demarcation of pathological changes in individual retinal layers is possible with the HD-OCT. Summation images permit accurate localization of a scan. Topographic and volumetric evaluations enable analysis of individual compartments in the entire scanned area and are suitable for monitoring treatment of CNV with anti-VEGF therapy. The raster method decreases the dependence on exploratory methods that have been necessary until now to generate retinal thickness maps.


CONCLUSIONS
This report presents initial experience in using a raster scanning HD-OCT system in patients with neovascular age-related macular degeneration and describes new evaluation functions that aid in obtaining more precise assessment of treatment effect and its impact on the retinal ultrastructure. The results of this study clearly show that development of high-resolution OCT systems in conjunction with development of novel treatment options for exudative diseases offers promising perspectives.
Ahlers
C
C
Universitätsklinik für Augenheilkunde, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090 Wien, Osterreich. christian.ahlers@meduniwien.ac.at
Geitzenauer
W
W
Simader
C
C
Stock
G
G
Golbaz
I
I
Polak
K
K
Georgopoulos
M
M
Schmidt-Erfurth
U
U
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D021621:Imaging, Three-Dimensional; D007231:Infant, Newborn; D008268:Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy; D010865:Pilot Projects; D011446:Prospective Studies; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000175:diagnosis; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab